What Is Microsatellite Instability and Why Does It Matter?

Microsatellite instability is a condition in which a cell’s DNA accumulates errors at an unusually high rate in specific repetitive stretches of genetic code called microsatellites. It matters because it turns up in a meaningful fraction of several common cancers and has become one of the most important biomarkers in modern oncology, directly shaping whether a patient receives immunotherapy, traditional chemotherapy, or an entirely different treatment plan. The story of MSI sits at the intersection of DNA repair, inherited cancer syndromes, and a revolution in how we treat tumors based on their molecular features rather than where in the body they grow.

What Microsatellites Are and How They Go Wrong

Scattered throughout your genome are short, repetitive sequences where one, two, or a few DNA letters repeat in tandem, sometimes dozens of times in a row. These are microsatellites. They serve various structural and regulatory roles, but their repetitive nature makes them inherently tricky for the cellular machinery that copies DNA. When a cell divides, the enzyme responsible for copying DNA can pause within these repeats, slip, and reattach in the wrong spot, producing a copy that is slightly too long or too short.

Research on how this slippage works has shown that the copying enzyme physically pauses inside the repeat and then detaches from the DNA strand, allowing the newly made strand to misalign before copying resumes.¹ For shorter microsatellites, a different error mechanism involving the raw building blocks of DNA may dominate, but as the repeat gets longer, strand slippage takes over as the primary source of mistakes.² In a healthy cell, these copying errors are caught and fixed almost immediately by a set of proteins collectively called the mismatch repair system. This repair pathway scans freshly copied DNA for mismatches and small insertions or deletions, then corrects them.³ When that repair system fails, the slippage errors pile up unchecked, and the microsatellites throughout the genome start gaining or losing repeats at a dramatically higher rate. That is microsatellite instability.

Two Routes to the Same Problem

Mismatch repair can fail for fundamentally different reasons, and distinguishing between them has real consequences for patients and their families.

The inherited route is Lynch syndrome, formerly called hereditary nonpolyposis colorectal cancer. People with Lynch syndrome are born with a faulty copy of one of the key mismatch repair genes, most commonly MSH2, MLH1, MSH6, or PMS2.⁴ Every cell in their body carries this inherited vulnerability. When the remaining working copy of the gene is knocked out by a random mutation in a given tissue, mismatch repair collapses in that cell line, microsatellite instability follows, and cancer risk climbs sharply. Lynch syndrome accounts for roughly 3% of all colorectal cancers and raises the lifetime risk of cancers in the colon, uterus, ovaries, stomach, and other organs.⁵

The sporadic route is more common. In most MSI-high tumors that arise without an inherited predisposition, the culprit is a chemical modification called promoter methylation that silences the MLH1 gene. Rather than a mutation that damages the gene’s code, methyl groups are added to the gene’s control region, effectively switching it off. In sporadic colorectal cancers with MSI, about half show MLH1 promoter methylation.⁶ A similar pattern holds in endometrial cancers, where researchers found MLH1 methylation in the vast majority of MSI-positive tumors but almost never in microsatellite-stable ones.⁷ The net effect on the tumor is the same: the repair system goes dark, errors accumulate, and the microsatellites become unstable.

Which Cancers Are Most Affected

MSI is not equally common across all cancer types. A large meta-analysis covering tens of thousands of patients estimated the overall prevalence of MSI-high status across 25 tumor types at roughly 14%, though that average masks enormous variation.⁸ Endometrial cancer consistently shows the highest rates, with pooled estimates around 22 to 27% depending on the study and the testing method used.⁹ Colorectal cancer follows at roughly 10 to 13%, and gastric cancer sits in a similar range. Small bowel cancers are less common overall but show MSI-high rates of around 14 to 21%.

In rarer or less-studied tumor types, MSI-high status is uncommon. A study using circulating tumor DNA from nearly 172,000 patients across many cancer types found that only about 1.4% of the full population was MSI-high, illustrating how the prevalence drops when you look beyond the cancers where MSI concentrates.¹⁰

The prognostic meaning of MSI varies by cancer type. In colorectal cancer, MSI-high tumors generally carry a better prognosis than microsatellite-stable tumors, particularly in early-stage disease. In endometrial cancer, the picture is less clear. Population-based studies have found that despite being common, MSI-high status does not significantly affect survival in endometrial cancer after adjusting for stage and grade.¹¹ A separate large study of over 250 endometrial cancers confirmed that MSI was frequent but found no association with prognosis.¹²

How Doctors Test for MSI

There are two main approaches used in clinical practice. The first is immunohistochemistry, or IHC, which stains a tissue sample with antibodies that target the four main mismatch repair proteins. If one or more proteins are absent, the tumor is classified as mismatch repair deficient, which is functionally equivalent to MSI-high in most cases. The second approach uses molecular techniques, traditionally a PCR-based assay that directly measures the lengths of specific microsatellite markers in tumor DNA and compares them to normal tissue. If enough markers show length changes, the tumor is MSI-high.

In colorectal cancer, the two methods agree almost perfectly. A large population-based study of nearly 600 colon cancer cases found that about 97% of MSI-high tumors showed abnormal IHC results, and about 98% of IHC-abnormal cases tested as MSI-high by PCR.¹³ Endometrial cancer is trickier. Molecular MSI assays show lower sensitivity for detecting mismatch repair deficiency in endometrial tumors, with sensitivity dropping as low as 58 to 75% depending on the platform, suggesting that combining both IHC and molecular testing gives the most complete picture.¹⁴

Next-generation sequencing is increasingly replacing or supplementing these older methods. NGS-based algorithms can detect MSI from the same tumor sequencing panel used to look for other actionable mutations, avoiding the need for a separate test. One such algorithm achieved close to 99% accuracy against PCR-based methods in validation.¹⁵ A persistent challenge, though, is that tumors with low amounts of cancer DNA in the sample can fool these algorithms. A deep-learning approach called MiMSI was developed specifically to address this, achieving higher sensitivity on difficult low-purity samples than existing tools.¹⁶

Why MSI-High Tumors Light Up the Immune System

The accumulation of errors at microsatellite sites is not just a bookkeeping problem. Many microsatellites sit inside or near genes. When a coding microsatellite gains or loses repeats, it throws the reading frame off, producing a truncated or garbled protein. These abnormal proteins look foreign to the immune system. In MSI-high tumors, hundreds of genes can be affected this way, generating a large pool of neoantigens, which are essentially molecular flags that mark the tumor cell as abnormal.¹⁷

The result is that MSI-high tumors tend to be heavily infiltrated by immune cells, particularly certain types of T-cells and macrophages. Studies of colorectal cancers have found significantly higher levels of gamma-delta T-cells, helper T-cells, and activated macrophages in MSI-high tumors compared to microsatellite-stable ones.¹⁸ This brisk immune response is a double-edged sword for the tumor: on one hand, the immune cells are actively fighting the cancer. On the other, the tumor often survives by upregulating checkpoint proteins that tell those immune cells to stand down. That tug-of-war is exactly what makes MSI-high tumors vulnerable to immunotherapy.

The Immunotherapy Revolution

In 2017, pembrolizumab became the first cancer drug ever approved by the FDA based on a molecular feature rather than the organ of origin. The approval covered any unresectable or metastatic solid tumor that tested MSI-high or mismatch repair deficient, regardless of whether it was colorectal, endometrial, gastric, or something rarer.¹⁹ Dostarlimab, another checkpoint inhibitor, received similar approval in 2021.

The clinical trial data behind these approvals have held up over time. The KEYNOTE-158 study, which tested pembrolizumab across multiple MSI-high cancer types, reported an overall response rate of about 31%, with responses lasting a median of nearly four years.²⁰ The earlier KEYNOTE-016 study, which first demonstrated the concept, now has ten-year follow-up data. It reported an overall response rate of 58%, with a disease control rate of 76%. Median overall survival was about 81 months, and the ten-year survival rate was about 47%, with some patients remaining in remission for over a decade.²¹ For patients with advanced cancers that have few other options, those numbers are striking.

When Standard Chemotherapy Backfires

Before the immunotherapy era, some oncologists noticed an uncomfortable pattern: MSI-high colon cancers did not seem to benefit from fluorouracil-based chemotherapy, which was (and still is) a backbone of adjuvant treatment for colorectal cancer. A landmark study published in the New England Journal of Medicine confirmed this, finding that patients with MSI-high colon cancer received no benefit from fluorouracil-based adjuvant chemotherapy, while patients with microsatellite-stable tumors did.²² A separate analysis confirmed the finding, showing no survival difference between treated and untreated patients when the tumor was MSI-high.²³

The leading explanation ties back to how mismatch repair works. Fluorouracil kills cancer cells partly by getting incorporated into DNA in a way that the mismatch repair system detects as an error, triggering cell death. If mismatch repair is already broken, the cell does not recognize the damage and does not self-destruct. This means that knowing a patient’s MSI status is not just useful for deciding whether to add immunotherapy; it can also prevent the use of a chemotherapy regimen that is unlikely to help and could cause unnecessary side effects.

When MSI-High Tumors Resist Immunotherapy

An important misconception is that MSI-high status guarantees a response to checkpoint inhibitors. It does not. Across the large studies described above, roughly 40 to 70% of MSI-high patients do not achieve an objective tumor response. Several mechanisms of resistance have been identified. Tumors can lose the ability to display neoantigens on their surface by altering the cellular machinery responsible for antigen presentation. They can also reshape their local environment into an immunosuppressive zone, or upregulate alternative checkpoint molecules that are not blocked by the drug being used.²⁴ Research into overcoming these escape routes is active, but for now, MSI-high status is a strong reason to try immunotherapy, not a promise that it will work.

Universal Screening and What It Means for Families

Because MSI testing can uncover Lynch syndrome, there has been a push toward testing every newly diagnosed colorectal and endometrial cancer, regardless of the patient’s age or family history. The rationale is straightforward: about 3% of colorectal cancers and a meaningful share of endometrial cancers stem from Lynch syndrome, and identifying those patients opens the door to heightened cancer surveillance for their blood relatives.

Patient attitudes toward this kind of screening are generally positive. A survey of 189 newly diagnosed colorectal cancer patients found that 93% wanted to know their risk of hereditary cancer, and among those who received a positive Lynch syndrome screening result, 93% shared the result with at least one close family member.²⁵ A separate study found that about 81% of patients were willing to have their tumors screened if universal testing were available, though a majority also expected to be asked for consent first, rather than having the test run automatically.²⁶ The consent question remains unresolved in many institutions. Some centers run MSI testing on every qualifying tumor as standard pathology practice, treating it like any other lab test; others insist on an informed consent process that can delay results.

Liquid Biopsy and the Move Away from Tissue

Standard MSI testing requires a tumor tissue sample, which means a biopsy or surgical specimen. Researchers are now exploring whether MSI can be reliably detected from a simple blood draw by analyzing fragments of tumor DNA circulating in the bloodstream. The appeal is obvious: a blood test could monitor MSI status over time, catch changes during treatment, and potentially screen patients whose tumors are difficult or dangerous to biopsy.²⁷ Next-generation sequencing is the technology most likely to make this practical, because it offers the sensitivity needed to detect microsatellite length changes in the small amounts of tumor DNA present in blood.²⁸ This field is still early, but clinical adoption is gaining momentum.

EMAST, the Other Kind of Microsatellite Instability

Most clinical MSI testing focuses on mononucleotide repeats, the simplest type of microsatellite. But another form of instability has been described at longer, four-base-pair repeat sites. This pattern, called elevated microsatellite alterations at selected tetranucleotide repeats (EMAST), arises from problems with a different repair protein, MSH3, rather than the MLH1 or MSH2 genes involved in classical MSI.²⁹ Chronic inflammation appears to play a role: the inflammatory signaling molecule IL-6 can push the MSH3 protein out of the cell nucleus and into the cytoplasm, where it cannot do its job. This mechanism has been documented in ulcerative colitis, where EMAST-type changes increase as the tissue progresses toward cancer.³⁰

EMAST tumors have been linked to higher stage at diagnosis and worse prognosis in some studies, but the clinical significance is far from settled. Standard MSI testing does not detect EMAST, and there is no established treatment strategy for it. Whether EMAST represents a truly distinct biological category or simply an overlap zone between stable and classically MSI-high tumors is an open question.

The Gut Microbiome and Immunotherapy Response

Even among MSI-high patients treated with checkpoint inhibitors, response varies widely. Researchers have started looking at the gut microbiome as one explanation. A study of gastrointestinal cancer patients undergoing immunotherapy found clear differences in gut bacteria between those who responded to treatment and those who did not. Responders had higher levels of certain bacterial species and higher concentrations of short-chain fatty acids like butyrate in their stool. Their gut microbiome was also enriched for species linked to arginine metabolism, a pathway connected to immune cell function.³¹ This does not mean eating yogurt will make immunotherapy work, but it does suggest that the tumor’s molecular profile is only part of the story, and that factors outside the tumor itself can influence whether the immune system mounts an effective response.

Microsatellite Instability in Plants and Lab Animals

MSI is not a uniquely human problem. The mismatch repair system is ancient, and disrupting it produces microsatellite instability across a wide range of organisms. In mouse models, knocking out the MSH2 gene leads to detectable MSI throughout the normal colon, even before any cancer develops. Longer microsatellite repeats are the most sensitive to these changes, tending to contract rather than expand.³² Mice carrying a mutation in PMS2, another mismatch repair gene, develop increased MSI and intestinal tumors when combined with a second cancer-predisposing mutation.³³

Even plants experience microsatellite instability. Research on Arabidopsis, a common laboratory plant, found that the rate of microsatellite mutations increased dramatically as the plant aged, rising over 60-fold between early seedlings and mature plants.³⁴ This age-related rise in microsatellite mutation mirrors, at least broadly, what happens in aging human tissues and reinforces the idea that microsatellite instability is a fundamental consequence of how repetitive DNA sequences interact with the limits of the repair machinery, across all branches of life.